Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

PPBT

Purple Biotech Ltd ADR

Mar 21 • 04:00PM ET

2.73

Dollar change -0.03
Percentage change -0.91	%

Healthcare • Biotechnology • Israel • NASD

Peers: AMRN ADAP CRDF GNFT RDUS DVAX AFMD ONCT ATNM APVO

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-5.18	Insider Own	0.75%	Shs Outstand	2.65M	Perf Week	0.35%
Market Cap	7.25M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	2.63M	Perf Month	-15.85%
Income	-7.24M	PEG	-	EPS next Q	-	Inst Own	3.04%	Short Float	1.84%	Perf Quarter	-30.23%
Sales	0.00M	P/S	-	EPS this Y	-	Inst Trans	-99.73%	Short Ratio	1.05	Perf Half Y	-61.48%
Book/sh	12.71	P/B	0.22	EPS next Y	-	ROA	-17.80%	Short Interest	0.05M	Perf Year	-80.72%
Cash/sh	3.22	P/C	0.85	EPS next 5Y	-	ROE	-21.59%	52W Range	2.00 - 20.60	Perf YTD	-41.68%
Dividend Est.	-	P/FCF	-	EPS past 5Y	45.90%	ROI	-22.03%	52W High	-86.72%	Beta	0.60
Dividend TTM	-	Quick Ratio	2.23	Sales past 5Y	-20.00%	Gross Margin	-	52W Low	36.75%	ATR (14)	0.22
Dividend Ex-Date	-	Current Ratio	2.23	EPS Y/Y TTM	71.57%	Oper. Margin	-	RSI (14)	41.74	Volatility	7.47% 7.19%
Employees	9	Debt/Eq	0.01	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	33.00
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	95.97%	Payout	-	Rel Volume	0.22	Prev Close	2.76
Sales Surprise	-	EPS Surprise	-18.18%	Sales Q/Q	-	Earnings	Mar 10 BMO	Avg Volume	46.30K	Price	2.73
SMA20	-2.96%	SMA50	-13.24%	SMA200	-50.22%	Trades		Volume	9,975	Change	-0.91%

Mar-10-25 08:57AM	Purple Biotech Reports Fourth Quarter and Full-Year 2024 Financial Results (GlobeNewswire)
Mar-05-25 07:00AM	Purple Biotech Granted New U.S. Patent for NT219 in Combination with EGFR Antibody Therapy, Enhancing Global IP Protection in Major Markets (GlobeNewswire)
Feb-18-25 07:00AM	Purple Biotech Advances NT219 into Phase 2 Head and Neck Cancer Trial (GlobeNewswire)
Feb-03-25 07:00AM	Purple Biotech Announces Research Collaboration with the Icahn School of Medicine at Mount Sinai for CAPTN-3 Tri-Specific Antibody Platform (GlobeNewswire)
Dec-05-24 07:13AM	Purple Biotech Announces Closing of $2.8 Million Registered Direct Offering of American Depositary Shares (GlobeNewswire) -16.93%
08:23AM	Loading…
Dec-03-24 08:23AM	Purple Biotech Announces $2.8 Million Registered Direct Offering of American Depositary Shares (GlobeNewswire) -21.79%
Dec-02-24 07:00AM	Purple Biotech Reports Positive Final Results from Randomized Phase 2 Study of CM24 in Second Line Pancreatic Cancer (GlobeNewswire) +150.37%
Nov-15-24 07:00AM	Purple Biotech Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Nov-05-24 08:13AM	Purple Biotech Unveils Promising Biomarker for Cancer Therapy (TipRanks)
Nov-04-24 07:50AM	Purple Biotech Identifies Potential New Serum Biomarker for its Lead Oncology Therapeutic Candidate CM24: Associated with 79% Reduction in Risk of Death (GlobeNewswire)
Oct-25-24 07:20AM	Purple Biotech Presents New Data for its Novel Tri-Specific T Cell and NK Cell Engagers Antibody Platform, CAPTN-3, at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (GlobeNewswire) -9.35%
Oct-11-24 07:57AM	Purple Biotech Unveils CAPTN-3 Cancer Therapy (TipRanks)
Oct-10-24 07:30AM	Purple Biotech to Present Data for its Tri-Specific Antibody Platform CAPTN-3 at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
Sep-18-24 06:30AM	Purple Biotech Reports Additional Positive Interim Data from its Randomized Phase 2 Study with its Lead Oncology Therapeutic Candidate CM24 (GlobeNewswire)
Sep-16-24 09:38AM	Upcoming Stock Splits This Week (September 16 to September 20) Stay Invested (TipRanks)
07:00AM	Loading…
Sep-10-24 07:00AM	Purple Biotech to Present Data for its Lead Oncology Drug CM24 at the AACR Special Conference on Advances in Pancreatic Cancer Research (GlobeNewswire)
Aug-30-24 07:00AM	Purple Biotech to Participate at H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire) +6.30%
Aug-16-24 10:53PM	PPBT Stock Earnings: Purple Biotech Beats EPS for Q2 2024 (InvestorPlace)
08:12AM	Purple Biotech Reports Second Quarter 2024 Financial Results and Business Highlights (GlobeNewswire)
Jul-25-24 07:35AM	Purple Biotech Receives Extension to Regain Compliance with the Nasdaq's Minimum Bid Price Rule (GlobeNewswire)
Jul-10-24 07:30AM	Purple Biotech to Host Virtual KOL Event to Discuss Positive Interim Results from Phase 2 Pancreatic Cancer Study with CM24 on July 11, 2024 (GlobeNewswire) +15.31%
Jul-02-24 04:00PM	Purple Biotech Announces Closing of Exercise of Warrants for $2 Million Gross Proceeds (GlobeNewswire)
Jul-01-24 09:00AM	Purple Biotech Announces Exercise of Warrants for $2 Million Gross Proceeds (GlobeNewswire) -11.77%
Jun-27-24 07:45AM	Purple Biotech Reports Additional Positive Interim Results from its Randomized Phase 2 Pancreatic Cancer Study with CM24 Regarding a Potential Predictive Biomarker for Overall Survival Benefit (GlobeNewswire) -8.83%
Jun-01-24 08:00AM	Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic Cancer (GlobeNewswire)
May-21-24 01:52PM	PPBT Stock Earnings: Purple Biotech Beats EPS for Q1 2024 (InvestorPlace) +6.54%
07:30AM	Purple Biotech Reports First Quarter 2024 Financial Results (GlobeNewswire)
Apr-25-24 07:00AM	Purple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting (GlobeNewswire)
Mar-28-24 07:00AM	Purple Biotech to Present New Data On its Oncology Drug NT219 at AACR 2024 (GlobeNewswire) +9.66%
Mar-14-24 07:30AM	Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technology (GlobeNewswire)
09:55AM	Loading…
Mar-13-24 09:55AM	Here's Why Purple Biotech Ltd. Sponsored ADR (PPBT) Could be Great Choice for a Bottom Fisher (Zacks)
Mar-05-24 11:52PM	PPBT Stock Earnings: Purple Biotech Meets EPS for Q4 2023 (InvestorPlace)
07:55AM	Purple Biotech Reports Fourth Quarter and Full-Year 2023 Financial Results (GlobeNewswire)
Feb-27-24 07:00AM	Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024 (GlobeNewswire) -5.91%
Feb-13-24 07:00AM	Purple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 Trial (GlobeNewswire)
Feb-01-24 07:30AM	Purple Biotech Reaches Recommended Phase 2 Dose for NT219 (GlobeNewswire)
Dec-20-23 08:05AM	Purple Biotech Appoints Dr. Yael Margolin to its Board of Directors (GlobeNewswire) -9.17%
Dec-14-23 06:50AM	Purple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trial (GlobeNewswire)
Nov-21-23 06:50AM	Purple Biotech Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Nov-02-23 07:00AM	Purple Biotech Fortifies NT219 Patent Protection (GlobeNewswire)
Oct-19-23 03:55PM	Purple Biotech Announces Closing of $5 Million Registered Direct Offering (GlobeNewswire) +13.04%
Oct-17-23 08:00AM	Purple Biotech Announces $5 Million Registered Direct Offering (GlobeNewswire)
Oct-06-23 07:50AM	Purple Biotech Reports Potential Biomarker Data Support CM24s Mechanism of Action (GlobeNewswire)
Oct-03-23 07:50AM	Purple Biotech Reports Positive Interim and Preliminary Results from NT219 Phase 1/2 Study in R/M Head & Neck Cancer (GlobeNewswire) -8.18%
Sep-21-23 08:00AM	Purple Biotech to Present New CM24 Pancreatic Cancer Biomarker Data at AACR Special Conference on September 28, 2023 (GlobeNewswire) +8.82%
Aug-22-23 09:29AM	Purple Biotech Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Jul-11-23 08:15AM	Purple Biotech Reports Positive Results of CM24 Dose Escalation in Advanced Pancreatic Cancer Patients (GlobeNewswire) -7.72%
May-16-23 04:00PM	Purple Biotech Reports First Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Apr-25-23 08:00AM	Purple Biotech Debuts Scientific Advisory Board (GlobeNewswire)
Apr-19-23 08:15AM	Purple Biotech Reports New Preclinical Data on Potential of NT219 to Re-sensitize Resistant Tumors to Immune Checkpoint Inhibitors (GlobeNewswire)
Apr-18-23 07:00AM	Purple Biotech to Participate in Canaccord Genuity's 2023 Horizons in Oncology Virtual Conference (GlobeNewswire)
Mar-24-23 07:00AM	Purple Biotech Reports Temporary Medical Leave of CEO Gil Efron (GlobeNewswire) -5.11%
Mar-16-23 07:00AM	Purple Biotech Reports Biomarker Data from CM24 Phase 1 Dose Escalation Study (GlobeNewswire)
Feb-14-23 07:01AM	Purple Biotech Announces First Patient Dosed in Open Label, Randomized Part of CM24 Phase 2 Clinical Trial (GlobeNewswire) +6.68%
Feb-08-23 07:12AM	Purple Biotech Reports Fourth Quarter and Full-Year 2022 Financial Results (GlobeNewswire)
Feb-02-23 07:00AM	Purple Biotech Expands Pipeline of First-in-Class Therapeutics with Acquisition of Immunorizon and Its Portfolio of Tri-Specific Antibodies for the Treatment of Cancer (GlobeNewswire) +6.18%
Jan-03-23 07:00AM	Purple Biotech and Mor Research Applications Announce Research Collaboration to Identify Promising Investigational Oncology Treatments (GlobeNewswire)
Nov-15-22 07:00AM	Purple Biotech Presents New Data on Mechanism of Action for CM24 at the AACR Special Conference: Cancer Metastasis (GlobeNewswire) +5.37%
Nov-10-22 07:00AM	Purple Biotech to Present at the Jefferies London Healthcare Conference (GlobeNewswire)
Nov-08-22 07:53AM	Purple Biotech Reports Third Quarter 2022 Financial Results (GlobeNewswire) -5.63%
Nov-02-22 07:37AM	Purple Biotech Appoints Lior Fhima as Chief Financial Officer (GlobeNewswire)
Aug-04-22 07:30AM	Purple Biotech Reports Second Quarter 2022 Financial Results (GlobeNewswire)
Jul-14-22 07:30AM	Purple Biotech Announces Executive Leadership Changes (GlobeNewswire)
May-27-22 07:15AM	Purple Biotech Presents Phase 1 Interim Monotherapy Data for NT219 at ASCO 2022, Demonstrating Encouraging Safety & Efficacy Profile (GlobeNewswire) -6.21%
May-18-22 08:18AM	Purple Biotech Announces the Initiation of Phase 2 Study for CM24 in 2L PDAC Patients (GlobeNewswire) +7.02%
May-12-22 08:13AM	Purple Biotech Reports First Quarter 2022 Financial Results (GlobeNewswire) -6.80%
Apr-11-22 07:37AM	Purple Biotech Presents Positive Interim Phase 1b Study Results for CM24 at the American Association of Cancer Research 2022 Annual Meeting (GlobeNewswire) -29.97%
Feb-24-22 12:12AM	Could The Solid State plc (LON:SOLI) Ownership Structure Tell Us Something Useful? (Simply Wall St.)
Feb-09-22 07:00AM	Purple Biotech Reports Second Half and Full-Year 2021 Financial Results (GlobeNewswire)
Feb-04-22 07:35AM	Purple Biotech Issues Letter to Shareholders (GlobeNewswire) +6.12%
Jan-06-22 07:30AM	Purple Biotech Appoints Life Sciences Industry Investor Ori Hershkovitz to its Board of Directors (GlobeNewswire)
07:24AM	Is Solid State plc's(LON:SOLI) Recent Stock Performance Tethered To Its Strong Fundamentals? (Simply Wall St.)
Dec-09-21 07:30AM	Purple Biotech Appoints Senior Business Development Executive Fabien Sebille as Chief Business Officer (GlobeNewswire)
03:30AM	Is Now An Opportune Moment To Examine Solid State plc (LON:SOLI)? (Simply Wall St.)
Dec-06-21 07:30AM	Purple Biotech Announces Initiation of Part 2 of Ongoing Phase 1/2 Clinical Trial Evaluating NT219 for Treatment of Multiple Cancers Supporting Potential Expansion of Clinical Program (GlobeNewswire) +6.40%
Nov-03-21 07:30AM	Purple Biotech to Present at the Jefferies London Healthcare Conference (GlobeNewswire)
Oct-26-21 08:27AM	Purple Biotech Expands Research Collaboration in Immuno-Oncology in Combination with NT219 (GlobeNewswire)
Oct-22-21 06:00AM	Purple Biotech Announces Publication in Nature Cancer Demonstrating Mechanisms Behind Cancer Cell Persistence Frequency and Potential of NT219 to Reduce Therapeutic Resistance (GlobeNewswire)
Sep-24-21 07:38AM	We Think Solid State (LON:SOLI) Can Stay On Top Of Its Debt (Simply Wall St.)
Sep-13-21 07:00AM	Purple Biotech to Present Overview of Ongoing Phase 1b/2 Clinical Trial of CM24 for Treatment of Multiple Advanced Cancers at ESMO 2021 and Provides Clinical Update (GlobeNewswire)
Aug-05-21 08:30AM	Purple Biotech Provides Corporate Update and Reports First Half 2021 Financial Results (GlobeNewswire)
Jun-04-21 08:00AM	Purple Biotech Presents New Clinical Data from NT219 at the 2021 ASCO Annual Meeting (GlobeNewswire) -11.76%
May-26-21 07:38AM	Purple Biotech to Present at the Jefferies Virtual Healthcare Conference (GlobeNewswire)
May-20-21 07:00AM	Purple Biotech to Present New Clinical Data from NT219 at the 2021 ASCO Annual Meeting (GlobeNewswire) +8.21%
May-19-21 07:00AM	Purple Biotech Appoints Seasoned Biopharmaceutical Industry Executive Suzana Nahum-Zilberberg to Board of Directors (GlobeNewswire)
Apr-23-21 08:00AM	Purple Biotech Announces Dosing of First Patient in Phase 1b/2 Clinical Trial of CM24 in Advanced Cancer Patients (GlobeNewswire)
Apr-13-21 08:17AM	Purple Biotech Presents Additional Mechanism of Action Data for NT219 at American Association of Cancer Research 2021 Annual Meeting (GlobeNewswire)
Mar-19-21 08:00AM	Purple Biotech Announces Initiation of Phase 1b/2 Clinical Trial of CM24 for Treatment of Multiple Advanced Cancers (GlobeNewswire)
Mar-11-21 08:02AM	Purple Biotech to Present Additional Mechanism of Action Data for NT219 at American Association of Cancer Research 2021 Annual Meeting (GlobeNewswire)
Mar-03-21 07:00AM	Purple Biotech Appoints Biopharmaceutical Industry Veteran Robert Gagnon to Board of Directors (GlobeNewswire)
Mar-02-21 07:00AM	Purple Biotech Provides Corporate Update and Reports Second Half and Full Year 2020 Financial Results (GlobeNewswire) -6.32%
Jan-18-21 07:41AM	Purple Biotech to Present at the B. Riley Oncology Investor Conference (GlobeNewswire)
Jan-04-21 09:40AM	Purple Biotech to Ring the Nasdaq Stock Market Opening Bell (GlobeNewswire) +6.56%

Purple Biotech Ltd. is a development stage pharmaceutical company, which engages in drug development. It operates through two segments: Oncology, and Pain & Hypertension. The Oncology segment includes NT219, a therapeutic candidate which is a small molecule that targets two signal transduction pathways which are involved in the development of cancer drug resistance mechanisms, and which is currently in the late pre-clinical stage of development. The Pain & Hypertension segment includes Consensi, a combination drug for the simultaneous treatment of two clinical conditions, pain caused by osteoarthritis and hypertension (high blood pressure), which can be pre-existing or caused by the treatment for osteoarthritis. The company was founded by John Paul Waymack on August 12, 1968 and is headquartered in Rehovot, Israel.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PPBT

Purple Biotech Ltd ADR

Upgrade your FINVIZ experience